Helsinn seeks SCOTUS review of patent case
05-03-2018
Federal Circuit reverses district court’s on-sale bar ruling
02-05-2017
renaschild / iStockphoto.com
The US Supreme Court has agreed to hear a dispute over whether confidential sales of an invention can trigger the on-sale bar and invalidate a patent under the America Invents Act (AIA).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Helsinn Healthcare, Teva Pharmaceuticals, cancer, cancer treatment, US Supreme Court, Eisai, chemotherapy, Federal Circuit
